Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
| Status: | Recruiting |
|---|---|
| Conditions: | Anemia, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/2/2016 |
| Start Date: | August 2002 |
| End Date: | June 2016 |
| Contact: | Madeline Cantini, BSN |
| Email: | Madeline.Cantini@uth.tmc.edu |
| Phone: | 713-500-8377 |
To correlate the Human Leukocyte Antigen type and genetic defect with hemophilia A.
One of the most serious complications of treatment in patients with hemophilia A or
hemophilia B is the development of an inhibitor, which is an antibody that neutralizes the
factor VIII or IX coagulant activity. Up to one fourth of patients with severe hemophilia A
develop an inhibitor but at present it is not possible to predict which patients will
develop such antibody. The ability to predict an inhibitor development at an individual
level would greatly improve therapeutic approach to this serious problem
hemophilia B is the development of an inhibitor, which is an antibody that neutralizes the
factor VIII or IX coagulant activity. Up to one fourth of patients with severe hemophilia A
develop an inhibitor but at present it is not possible to predict which patients will
develop such antibody. The ability to predict an inhibitor development at an individual
level would greatly improve therapeutic approach to this serious problem
Inclusion Criteria:
- Severe Hemophilia A with an inhibitor level of 0.6 B.U. or higher
Exclusion Criteria:
- Severe Hemophilia A with a negative inhibitor
We found this trial at
1
site
Click here to add this to my saved trials
